Summary for Tradename: NIASPAN
Clinical Trials for: NIASPAN
Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)(COMPLETED)
Status: Completed Condition: Hypercholesterolemia; Hyperlipidemia
Biosynthesis of PGD2 in Vivo
Status: Completed Condition: Healthy Volunteer
Niacin on Immune Activation : a Proof-of-concept Study
Status: Recruiting Condition: HIV
Randomized, Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery
Status: Completed Condition: Ischemic Stroke
Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis
Status: Completed Condition: Healthy Volunteers
Comparison of TRIA-662 500 mg and Niaspan 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions
Status: Completed Condition: Healthy
Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia
Status: Completed Condition: Dyslipidemia
Evaluation of the Effect of NICOtinic Acid (Niacin) on Elevated Lipoprotein(a) Levels (NICOLa Study)
Status: Active, not recruiting Condition: Elevated Lipoprotein(a) Levels
A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)
Status: Completed Condition: Hypercholesterolemia
Short-term Effect of Extended-release Niacin on Endothelial Function.
Status: Completed Condition: Hypoalphalipoproteinemia
Courtesy of ClinicalTrials.org
See more clinical trials for this drug
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Type||RLD||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|TABLET, EXTENDED RELEASE;ORAL||020381||Jul 28, 1997||DISCN||No||6,080,428||<disabled>||<disabled>|
|TABLET, EXTENDED RELEASE;ORAL||020381||Jul 28, 1997||DISCN||No||6,129,930||<disabled>||<disabled>|
|TABLET, EXTENDED RELEASE;ORAL||020381||Jul 28, 1997||DISCN||No||6,406,715||<disabled>||<disabled>|
|TABLET, EXTENDED RELEASE;ORAL||020381||Jul 28, 1997||DISCN||No||6,746,691||<disabled>||<disabled>|
|This preview shows a limited data set|
Complete access is available with a Subscription
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639